Showing results (51-60 of 67) with videos related to
Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomasAdília Hormigo, Bin Gu, Sasan Karimi, et al.Journal of Cranio-Maxillo-Facial Surgery : Official Publication of the European Association for Cranio-Maxillo-Facial Surgery|July 6, 2016
Objective assessment of trismus in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT)Adepitan A Owosho, Luciana M Pedreira Ramalho, Haley I Rosenberg, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2003
Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumorsCristina R Antonescu, Gunhild Sommer, Lisa Sarran, et al.Biorxiv : the Preprint Server for Biology|January 30, 2023
Keratinocytes coordinate inflammatory responses and regulate development of secondary lymphedemaHyeung Ju Park, Raghu P Kataru, Jinyeon Shin, et al.Leukemia & Lymphoma|August 10, 2011
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary diseaseHeather Landau, Neeta Pandit-Taskar, Hani Hassoun, et al.Journal of the American Society of Cytopathology|July 3, 2026
Diagnosis of granulomatous inflammation in thoracic small biopsies and fine needle aspiration specimens: a multi-institutional studyLuisa Ricaurte Archila, Annie Elizabeth Abraham, Adebowale J Adeniran, et al.British Journal of Haematology|September 28, 2007
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trialAdam D Cohen, Ping Zhou, Joanne Chou, et al.Journal of Neuro-Oncology|June 29, 2011
Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomasFabio M Iwamoto, Andreas F Hottinger, Sasan Karimi, et al.Neuro-Oncology|August 12, 2011
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomasFabio M Iwamoto, Andreas F Hottinger, Sasan Karimi, et al.Annals of Neurology|March 11, 2011
YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphomaAndreas F Hottinger, Fabio M Iwamoto, Sasan Karimi, et al.Pageof 7